Kybella FAQS

What does it do?

The active ingredient in KYBELLA® is synthetic deoxycholic acid. When injected into the fat beneath the chin, KYBELLA® destroys fat cells, resulting in a noticeable reduction in fullness under the chin. Once destroyed, these cells can no longer store or accumulate fat, so further treatment is not expected once you reach your desired aesthetic goal. KYBELLA® is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.”
It is not known if KYBELLA® is safe and effective for the treatment of fat outside of the submental area or in children under 18 years of age.


Where is Treatment Performed?

Before starting treatment, your healthcare specialist will examine the area under and around your chin to determine if KYBELLA® is right for you. Then, your specialist will tailor your treatment to the amount of fat under the chin and your aesthetic goals.


How Long Do Results Last?

The fat cells disintegrate and are absorbed by the body over 6-12 weeks.



The overall recovery timeline is about one month according to Allergan, the company that makes Kybella. This is why it's recommended that you wait at least one month between treatments, too.


Estimated Cost

$700 + 


How Long Do Treatments Last?

Treatment can only be administered by a KYBELLA®-trained healthcare specialist. At each treatment, you will receive multiple small injections under your chin, and the injection process takes about 15 to 20 minutes. The exact number of injections will depend on the amount of fat you have under your chin and your desired profile.


Are You A Candidate?

The ideal candidate for Kybella is a person with excess neck fat under the chin, who wants to avoid surgery such as liposuction. This ideal candidate also realizes that Kybella treatment requires more time commitment before seeing results, unlike the faster change with surgery.



KYBELLA® (deoxycholic acid) injection is contraindicated in the presence of infection at the injection sites. Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported during clinical trials.